Agilent Technologies, Inc. (A) Partners With AI Firm Lunit to Advance Cancer Diagnostics

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Agilent Technologies, Inc. is one of them.

Agilent Technologies, Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical solutions, providing instruments, software, and services for pharmaceutical, biotech, clinical, and environmental applications.

In Q3 fiscal 2025, the corporation reported non-GAAP earnings per share (EPS) of $1.37, surpassing analyst expectations, with revenue growing 10.1% year-over-year to $1.74 billion across its Life Sciences and Diagnostics, CrossLab, and Applied Markets segments. The company issued strong guidance for Q4 and fiscal year 2025, signaling continued revenue and earnings growth.

Highlighting its innovation strategy, Agilent Technologies, Inc. (NYSE:A) announced a strategic partnership with Lunit, an AI diagnostics firm specializing in cancer detection. The collaboration will integrate the firm’s tissue diagnostic expertise with Lunit’s AI algorithms to co-develop next-generation companion diagnostics, aiming to enhance biomarker testing precision and patient treatment options. This initiative underscores business’ focus on AI-driven precision medicine, a rapidly growing area in healthcare.

Agilent Technologies, Inc. (NYSE:A) also demonstrated commitment to shareholder returns by declaring a quarterly cash dividend of $0.2480 per share, above its 10-year average, with an ex-dividend date of September 30, 2025. The company participated in the 2025 Bank of America Global Healthcare Conference and has established an Open Biopharma Research Hub with Chungnam National University to accelerate innovation in biopharmaceutical development.

While we acknowledge the potential of A as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.